<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05038254</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0702</org_study_id>
    <secondary_id>NCI-2021-07464</secondary_id>
    <secondary_id>2020-0702</secondary_id>
    <nct_id>NCT05038254</nct_id>
  </id_info>
  <brief_title>Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events</brief_title>
  <official_title>There Is No Place Like Home- A Pragmatic Effectiveness Trial of Technology-Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies if enhanced outpatient symptom management with telemedicine and&#xD;
      remote monitoring can help reduce acute care visit due to chemotherapy-related adverse&#xD;
      events. Receiving telemedicine and remote monitoring may help patients have better outcomes&#xD;
      (such as fewer avoidable emergency room visits and hospitalizations, better quality of life,&#xD;
      fewer symptoms, and fewer treatment delays) than patients who receive usual care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Determine the efficacy of remote patient monitoring (RPM) on improving clinical outcomes.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. Evaluate the following patient-centered outcomes: treatment delays, health-related&#xD;
      quality-of-life (HRQOL), patient activation, and family caregiver-experience.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients receive standard of care consisting of oncology care provided via&#xD;
      telemedicine.&#xD;
&#xD;
      ARM II: Patients receive standard of care consisting of oncology care provided via&#xD;
      telemedicine. Patients also undergo remote monitoring.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of acute care visits</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Defined as the proportion of unique oncology patients with emergency room visits or hospital admission over a 3-month period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in health-related quality of life (HRQOL)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>HRQOL will be assessed using the Patient Reported Outcomes Measurement Information System (PROMIS) Profile-29 version 2.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient engagement</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Patient engagement will be evaluated with the 13-item Patient Activation Measure (PAM), which assesses knowledge, skill, and self-efficacy for self-management of health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in symptom management</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Daily symptoms will be measured using the Common Terminology Criteria for Adverse Events version 5.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Clinical Stage IV Esophageal Adenocarcinoma AJCC v8</condition>
  <condition>Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8</condition>
  <condition>Clinical Stage IV Gastric Cancer AJCC v8</condition>
  <condition>Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8</condition>
  <condition>Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8</condition>
  <condition>Clinical Stage IVA Gastric Cancer AJCC v8</condition>
  <condition>Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8</condition>
  <condition>Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8</condition>
  <condition>Clinical Stage IVB Gastric Cancer AJCC v8</condition>
  <condition>Metastatic Colon Carcinoma</condition>
  <condition>Metastatic Esophageal Carcinoma</condition>
  <condition>Metastatic Gastric Carcinoma</condition>
  <condition>Metastatic Liver Carcinoma</condition>
  <condition>Metastatic Malignant Digestive System Neoplasm</condition>
  <condition>Metastatic Malignant Small Intestinal Neoplasm</condition>
  <condition>Metastatic Malignant Thoracic Neoplasm</condition>
  <condition>Metastatic Pancreatic Carcinoma</condition>
  <condition>Metastatic Rectal Carcinoma</condition>
  <condition>Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8</condition>
  <condition>Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8</condition>
  <condition>Pathologic Stage IV Gastric Cancer AJCC v8</condition>
  <condition>Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8</condition>
  <condition>Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8</condition>
  <condition>Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8</condition>
  <condition>Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8</condition>
  <condition>Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8</condition>
  <condition>Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8</condition>
  <condition>Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8</condition>
  <condition>Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8</condition>
  <condition>Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8</condition>
  <condition>Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8</condition>
  <condition>Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8</condition>
  <condition>Stage IV Colon Cancer AJCC v8</condition>
  <condition>Stage IV Hepatocellular Carcinoma AJCC v8</condition>
  <condition>Stage IV Pancreatic Cancer AJCC v8</condition>
  <condition>Stage IV Rectal Cancer AJCC v8</condition>
  <condition>Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8</condition>
  <condition>Stage IVA Colon Cancer AJCC v8</condition>
  <condition>Stage IVA Hepatocellular Carcinoma AJCC v8</condition>
  <condition>Stage IVA Rectal Cancer AJCC v8</condition>
  <condition>Stage IVB Colon Cancer AJCC v8</condition>
  <condition>Stage IVB Hepatocellular Carcinoma AJCC v8</condition>
  <condition>Stage IVB Rectal Cancer AJCC v8</condition>
  <condition>Stage IVC Colon Cancer AJCC v8</condition>
  <condition>Stage IVC Rectal Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive standard of care consisting of oncology care provided via telemedicine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (standard of care, remote monitoring)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive standard of care consisting of oncology care provided via telemedicine. Patients also undergo remote monitoring.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Practice</intervention_name>
    <description>Receive standard of care telemedicine</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (standard of care, remote monitoring)</arm_group_label>
    <other_name>standard of care</other_name>
    <other_name>standard therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Patient Monitoring</intervention_name>
    <description>Undergo remote monitoring</description>
    <arm_group_label>Arm II (standard of care, remote monitoring)</arm_group_label>
    <other_name>medical monitoring</other_name>
    <other_name>monitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (standard of care, remote monitoring)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (&gt;= 18 years)&#xD;
&#xD;
          -  English- fluent with metastatic thoracic and gastrointestinal (esophagus, stomach,&#xD;
             liver, pancreas, small bowel, colon, and rectum) who are scheduled to initiate&#xD;
             outpatient chemotherapy (cycle 1, dose 1) at M D Anderson Cancer Center (MDACC) (Texas&#xD;
             Medical Center location)&#xD;
&#xD;
          -  Their adult (&gt;= 18 years) patient-identified or self-identified primary caregivers&#xD;
&#xD;
          -  Patients may participate if they do not have a caregiver, or if their caregiver&#xD;
             declines participation; however, caregivers may participate only if the patient&#xD;
             consents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients receiving investigational drug treatments or concurrently enrolled in a phase&#xD;
             1 clinical trial will be excluded due to the associated structured reporting and&#xD;
             regulatory requirements&#xD;
&#xD;
          -  Patients with a requirement for inpatient infusion (i.e. CAR-T cell therapy), living&#xD;
             in institutional settings (i.e. prison), with a history of dementia, physical&#xD;
             disability or neurological deficits that prohibit ability to report symptom burden&#xD;
             will also be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anaeze Offodile</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anaeze Offodile</last_name>
      <phone>713-563-6785</phone>
      <email>ACOffodile@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Anaeze Offodile</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 30, 2021</study_first_submitted>
  <study_first_submitted_qc>September 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Thoracic Neoplasms</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

